B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think
B-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an alternative to rituximab in the management of diff...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-03-01
|
| Seri Bilgileri: | Kidney Medicine |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2590059526000294 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|